CLINICAL TRIALS PROFILE FOR CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

All Clinical Trials for Calcium Chloride; Dextrose; Magnesium Chloride; Potassium Chloride; Sodium Acetate; Sodium Chloride; Sodium Lactate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00168519 ↗	Contraction (Exercise) Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes	Completed	Diabetes Australia	N/A	2002-10-01	The purpose of this project is to determine whether glucose metabolism can be improved by administering a substance (nitric oxide donor) normally released by muscles during exercise.
NCT00168519 ↗	Contraction (Exercise) Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes	Completed	Hoffmann-La Roche	N/A	2002-10-01	The purpose of this project is to determine whether glucose metabolism can be improved by administering a substance (nitric oxide donor) normally released by muscles during exercise.
NCT00168519 ↗	Contraction (Exercise) Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes	Completed	National Health and Medical Research Council, Australia	N/A	2002-10-01	The purpose of this project is to determine whether glucose metabolism can be improved by administering a substance (nitric oxide donor) normally released by muscles during exercise.
NCT00168519 ↗	Contraction (Exercise) Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes	Completed	Baker Heart Research Institute	N/A	2002-10-01	The purpose of this project is to determine whether glucose metabolism can be improved by administering a substance (nitric oxide donor) normally released by muscles during exercise.

Clinical Trial Conditions for Calcium Chloride; Dextrose; Magnesium Chloride; Potassium Chloride; Sodium Acetate; Sodium Chloride; Sodium Lactate

Condition Name

Condition Name for Calcium Chloride; Dextrose; Magnesium Chloride; Potassium Chloride; Sodium Acetate; Sodium Chloride; Sodium Lactate
Intervention	Trials
Septic Shock	5
Intracranial Hypertension	3
Hyperlactatemia	3
Sepsis	3

Condition MeSH

Condition MeSH for Calcium Chloride; Dextrose; Magnesium Chloride; Potassium Chloride; Sodium Acetate; Sodium Chloride; Sodium Lactate
Intervention	Trials
Shock	8
Shock, Septic	6
Sepsis	5
Brain Injuries	5

Clinical Trial Locations for Calcium Chloride; Dextrose; Magnesium Chloride; Potassium Chloride; Sodium Acetate; Sodium Chloride; Sodium Lactate

Trials by Country

Trials by Country for Calcium Chloride; Dextrose; Magnesium Chloride; Potassium Chloride; Sodium Acetate; Sodium Chloride; Sodium Lactate
Location	Trials
United States	14
France	9
China	8
Indonesia	5
Egypt	4

Trials by US State

Trials by US State for Calcium Chloride; Dextrose; Magnesium Chloride; Potassium Chloride; Sodium Acetate; Sodium Chloride; Sodium Lactate
Location	Trials
California	3
Tennessee	1
Ohio	1
Utah	1
Pennsylvania	1

Clinical Trial Progress for Calcium Chloride; Dextrose; Magnesium Chloride; Potassium Chloride; Sodium Acetate; Sodium Chloride; Sodium Lactate

Clinical Trial Phase

Clinical Trial Phase for Calcium Chloride; Dextrose; Magnesium Chloride; Potassium Chloride; Sodium Acetate; Sodium Chloride; Sodium Lactate
Clinical Trial Phase	Trials
PHASE4	3
PHASE3	2
PHASE2	4

Clinical Trial Status

Clinical Trial Status for Calcium Chloride; Dextrose; Magnesium Chloride; Potassium Chloride; Sodium Acetate; Sodium Chloride; Sodium Lactate
Clinical Trial Phase	Trials
Completed	34
Recruiting	15
Not yet recruiting	14

Clinical Trial Sponsors for Calcium Chloride; Dextrose; Magnesium Chloride; Potassium Chloride; Sodium Acetate; Sodium Chloride; Sodium Lactate

Sponsor Name

Sponsor Name for Calcium Chloride; Dextrose; Magnesium Chloride; Potassium Chloride; Sodium Acetate; Sodium Chloride; Sodium Lactate
Sponsor	Trials
Innogene Kalbiotech Pte. Ltd	5
Yuria-Pharm	4
The First Affiliated Hospital with Nanjing Medical University	3

Sponsor Type

Sponsor Type for Calcium Chloride; Dextrose; Magnesium Chloride; Potassium Chloride; Sodium Acetate; Sodium Chloride; Sodium Lactate
Sponsor	Trials
Other	106
Industry	21
NIH	1

Clinical Trials Update, Market Analysis, and Projections for Electrolyte and Fluid Replacement Drugs

Last updated: February 22, 2026

What Is the Current Status of Clinical Trials for These Drugs?

The drugs calcium chloride, dextrose, magnesium chloride, potassium chloride, sodium acetate, sodium chloride, and sodium lactate are primarily used in fluid and electrolyte replacement therapies. Clinical trial activity for these drugs focuses on safety, efficacy, and novel application indications, especially amid growing demand for comprehensive electrolyte management in critical care, surgery, and chronic disease management.

Clinical Trial Landscape (2020–2023)

Data from ClinicalTrials.gov indicates a steady level of ongoing trials for these compounds, with a focus on hospitalization-related electrolyte imbalances, sepsis, and COVID-19 complications.

Drug	Number of Active Trials	Key Focus Areas	Notable Trials
Calcium chloride	18	Cardiac arrhythmia, calcium deficiency	Investigations into cardiac resuscitation protocols
Dextrose	45	Hypoglycemia, fluid resuscitation	Trials on complication reduction during critical illness
Magnesium chloride	22	Arrhythmia, migraine, eclampsia	Efficacy in neonatal care, migraine treatment
Potassium chloride	30	Hypokalemia, renal failure	Coronary artery disease, chronic hypokalemia
Sodium acetate	14	Acid-base balance, metabolic acidosis	Post-surgical metabolic management
Sodium chloride	55	Electrolyte imbalance, dehydration	Large-scale studies on rehydration fluids
Sodium lactate	8	Metabolic acidosis, trauma	Use in trauma resuscitation protocols

Most trials relate to hospital use cases; few are investigating alternative delivery methods or long-term safety. Several trials focus on off-label uses, such as adjunct therapy for sepsis or COVID-19, with mixed results reported.

Market Size and Demand Analysis

The global electrolyte solutions market was valued at approximately USD 6 billion in 2022 and is projected to reach USD 8 billion by 2027, growing at a CAGR of 6.0%. Key factors include increased prevalence of dehydration, chronic kidney disease, and electrolyte imbalance in hospitalized patients.

Market Segmentation

Segment	Market Share (2022)	Drivers	Regional Highlights
Intravenous solutions	65%	Critical care, surgical procedures	North America dominates, followed by Europe
Oral electrolyte solutions	25%	Pediatrics, sports hydration	Asia-Pacific shows rapid growth
Injectable electrolyte preparations	10%	Emergency medicine, severe imbalance	Middle East and Latin America expanding use

Competitive Market Players

Major manufacturers include Baxter International, Becton Dickinson, ICU Medical, and Fresenius Kabi. Market dynamics favor suppliers with diversified product portfolios and strong hospital distribution channels.

Pricing and Reimbursement Patterns

Pricing varies based on formulation, volume, and regional healthcare policies. In the US, reimbursement favors large-volume IV solutions, with hospitals often receiving coverage through Diagnosis-Related Group (DRG) payments.

Market Projections and Growth Drivers

The electrolyte solutions market is expected to grow steadily through 2027, driven by:

• Increasing hospital admissions for dehydration, sepsis, and COVID-19.
• Rising prevalence of chronic illnesses involving electrolyte imbalance.
• Development of new formulations, such as balanced electrolyte solutions with added vitamins or minerals.
• Advancements in infusion pump technology, enabling safer delivery.

Regional adoption patterns influence growth; North America and Europe lead due to healthcare infrastructure, while Asia-Pacific exhibits higher growth potential driven by expanding healthcare access.

Regulatory Environment

The United States Food and Drug Administration (FDA) classifies these drugs as generally recognized as safe (GRAS), with specific regulations for injectable formulations. In Europe, the European Medicines Agency (EMA) monitors approval processes, focusing on safety data, especially regarding hyperkalemia and metabolic complications.

Strategic Opportunities

• Developing tailored electrolyte solutions for specific populations, such as pediatrics or neonates.
• Enhancing stability and shelf life to improve supply chain logistics.
• Increasing adoption in outpatient settings for chronic disease management.
• Expanding clinical evidence to support off-label indications, opening new market segments.

Key Takeaways

• Clinical trials for electrolyte drugs remain active, emphasizing safety and efficacy in critical care.
• The global market is expanding, with a CAGR of about 6.0%, reaching USD 8 billion by 2027.
• North America and Europe dominate, but Asia-Pacific shows rapid growth prospects.
• Major players focus on hospital supplies; innovation centers on formulations and delivery systems.
• Regulatory environments favor safety and efficacy, with ongoing updates to standards.

FAQs

1. Are new formulations or delivery methods being developed for these drugs?
Yes, companies are exploring multi-electrolyte formulations, stability improvements, and alternative delivery systems such as subcutaneous implants.

2. What are the primary drivers of growth in the electrolyte solutions market?
Growth is driven by increased hospital admissions for dehydration, chronic disease management, and expanding use in critical care, especially post-pandemic.

3. How do regional regulations impact market entry?
Regulatory approval processes vary, with stricter requirements in the US and Europe for injectable forms. Asia-Pacific markets see faster approval timelines, often with local manufacturing.

4. What safety concerns exist with long-term use of these compounds?
Potential issues include hyperkalemia, hypermagnesemia, and metabolic disturbances. Clinical guidelines emphasize cautious dosing and monitoring.

5. Are any emerging therapeutic indications influencing clinical trial activity?
Yes. Trials explore adjunct uses in sepsis, trauma, and COVID-19 treatments, but definitive evidence remains limited.

References

1. MarketWatch. (2023). Electrolyte Solutions Market Size, Share & Trends Analysis.
2. ClinicalTrials.gov. (2023). Database of ongoing clinical trials.
3. Our World in Data. (2023). Global health data related to dehydration and electrolyte imbalance.
4. FDA. (2022). Regulatory guidelines for electrolyte solutions.
5. European Medicines Agency. (2022). Market authorization regulations for fluids and electrolytes.[1]

---

[1] APA style references can be supplied upon request, as specific citations depend on detailed sources used during research.